GALECTIN THERAPEUTICS INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
GALECTIN THERAPEUTICS INC. (GALT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $145.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-03-31
- GALECTIN THERAPEUTICS INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $145.00K, a 95.95% increase from fiscal 2024.
- GALECTIN THERAPEUTICS INC. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $74.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2025-12-31 | $145.00K 10-K · filed 2026-03-31 |
| 2024-12-31 | $74.00K 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |